Blood Peptide Markers: What the Research Shows

What are blood peptide markers and why are researchers measuring them in pregnancy?

Blood peptide markers are proteins the body produces naturally that researchers can measure in blood to learn what is happening inside tissues — and in pregnancy, scientists are measuring specific peptides to detect complications earlier than symptoms appear.

Peptides are short chains of amino acids, the same building blocks that make up proteins. One tissue sends a peptide into the bloodstream, and another tissue reads it. During pregnancy, the placenta, kidneys, and blood vessels all release peptides that shift in measurable ways when something goes wrong. Researchers track those shifts to build better diagnostic tools.

Two peptides researchers are actively studying in pregnant women are sFlt-1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor). Both regulate how blood vessels form and function. When the ratio between them rises — sFlt-1 climbs while PlGF drops — it signals that the placenta may not be getting enough blood flow, a pattern linked to preeclampsia, a dangerous blood-pressure condition. A 2025 analytical study evaluated laboratory methods for measuring sFlt-1 and PlGF, finding that accurate, standardized measurement matters because small errors in these ratios can change clinical decisions for women in that study population.

Researchers are also measuring peptides that may signal risk earlier in pregnancy. ELABELA is a peptide involved in blood pressure regulation and placental development. A 2025 study measured maternal serum ELABELA levels in women diagnosed with threatened miscarriage between 8 and 14 weeks of gestation, examining whether lower levels correlated with pregnancy loss — the goal being earlier identification of women who may need closer monitoring.

Salusin-β is another peptide drawing research attention. A 2025 study found that women in that study who developed gestational diabetes had independently lower serum salusin-β levels compared to women with uncomplicated pregnancies, raising the question of whether this peptide could eventually serve as an early metabolic marker.

None of these markers are yet standard clinical tests everywhere. Evidence gaps remain: researchers still need larger, more diverse study populations to confirm which thresholds are meaningful, which women benefit most from testing, and whether acting on these markers changes outcomes. The pregnant body produces a distinct and measurable peptide landscape — and reading it carefully may give clinicians a longer window to act.

This section is for general health education only and does not constitute medical advice. Speak with your healthcare provider about any concerns related to pregnancy, testing, or treatment.

What did the ELABELA study find in women with threatened miscarriage?

A 2025 study measured blood peptide markers — specifically serum ELABELA levels — in pregnant women between 8 and 14 weeks of gestation to see whether this peptide differed between those experiencing threatened miscarriage (called abortus imminens, meaning early signs that a pregnancy may be at risk) and those with healthy pregnancies. Women in this study who had threatened miscarriage showed significantly lower ELABELA levels in their blood compared to women with uncomplicated pregnancies at the same gestational stage, according to this PMID 42595351 study.

ELABELA is a small signaling protein — a peptide — that the placenta produces and that circulates in maternal blood. It acts on the apelin receptor system, which plays a role in blood vessel development and placental function. A standard blood draw can measure it, making it a candidate for non-invasive early pregnancy assessment.

The study found:

• Women in this study with threatened miscarriage had measurably lower serum ELABELA concentrations than women with ongoing healthy pregnancies at the same weeks of gestation.
• The difference was statistically significant, meaning it was unlikely to be due to chance alone — though statistical significance does not automatically mean clinical usefulness.
• The research covered weeks 8 through 14, a window when placental development is active and when many pregnancy losses occur.

The study did not establish that low ELABELA causes miscarriage, or that measuring it can predict which pregnancies will continue and which will not. Correlation between a marker and an outcome is not the same as causation. The researchers also did not test any intervention — no treatment was given, and no clinical protocol was evaluated.

This was a single study with a defined population. The findings need replication in larger, more diverse groups before ELABELA could be considered a reliable clinical marker. The study did not report data by age subgroup, prior pregnancy history, or other variables that affect pregnancy outcomes. PMID 42595351 represents early-stage observational evidence, not a basis for clinical decision-making.

If you are pregnant and concerned about early pregnancy symptoms, speak with your obstetric care provider. This section describes what one study observed — it is not medical advice.

How accurate are PlGF assays for detecting preeclampsia risk?

PlGF assays — tests that measure blood peptide markers in a pregnant person's circulation — show strong analytical accuracy for detecting preeclampsia risk, though no single test gives a definitive yes or no answer on its own. PlGF (placental growth factor) is a small signaling protein made by the placenta; low levels in blood can signal that the placenta is not developing normally, which raises the risk of preeclampsia, a serious blood pressure condition in pregnancy.

A 2025 analytical study evaluated the Revvity sFlt-1 and PlGF methods across multiple performance dimensions. That study tested precision, linearity, and agreement between measurement platforms — the technical checks labs run before trusting a result in clinical care. Women in this study and the associated sample sets showed:

• Precision was high: repeated measurements of the same sample produced consistent results within acceptable ranges.
• The assays performed well across a wide concentration range, meaning they could detect both very low and very high PlGF levels accurately.
• The sFlt-1/PlGF ratio — a combined calculation using two peptide markers — showed strong agreement between the Revvity platform and reference methods.

What the trial did not establish is whether these assay results, on their own, predict clinical outcomes for any individual pregnant person. Accuracy in a lab setting and accuracy in predicting who will develop preeclampsia are related but different questions.

Several evidence gaps matter here. The Revvity study focused on analytical performance, not on a diverse population sample, so results may not reflect accuracy across all gestational ages, body compositions, or underlying conditions. PlGF levels shift across pregnancy, which means a result's meaning depends on how many weeks along a person is when the sample is taken.

Clinicians pair PlGF or sFlt-1/PlGF ratio results with blood pressure readings, urine protein levels, and clinical history — they do not use them in isolation. A low PlGF reading raises concern. It does not confirm a diagnosis. Ask your care team what threshold your specific lab uses and how they interpret results at your gestational age.

This content is for general health education only and is not medical advice. Talk with a qualified healthcare provider about any test results or decisions related to your pregnancy.

What does lower salusin-β mean for gestational diabetes risk?

Lower salusin-β — one of the blood peptide markers studied in gestational diabetes research — is independently associated with a higher likelihood of gestational diabetes mellitus (GDM) in pregnant women, according to one observational study. That association held even after researchers accounted for other known risk factors.

One study measured serum salusin-β in pregnant women and found that women in this study who developed GDM had significantly lower salusin-β concentrations than women with normal glucose tolerance. Salusin-β is a peptide — a short chain of amino acids — produced in the body and involved in regulating how cells respond to insulin. Insulin response matters during pregnancy because the body's demand for glucose management rises sharply, and when that system strains, blood sugar can climb into the GDM range.

The study reported that lower salusin-β levels were an independent predictor of GDM, meaning the association was not simply explained by body mass index, age, or other variables the researchers measured. Women in this study with GDM also showed higher fasting blood glucose and insulin resistance scores compared to the non-GDM group.

Three critical limits apply:

• This was an observational study. It shows an association, not a cause. Researchers cannot yet say whether low salusin-β causes GDM, results from the metabolic changes of GDM, or reflects a shared underlying process.
• The study did not test whether raising salusin-β levels — through any intervention — would reduce GDM risk. That question remains open.
• Women in this study represent one specific pregnant population. The findings may not apply across all ethnicities, ages, or pregnancy contexts.
• No salusin-β-based treatment for GDM is currently approved or established by this research.

The practical meaning right now is narrow: salusin-β may eventually serve as an early marker that clinicians measure alongside existing screening tools. Whether it adds predictive value beyond standard glucose testing is something future trials would need to establish.

Gestational diabetes screening and management decisions belong with a qualified obstetric care team. This section describes published research, not medical advice, and does not substitute for individualized clinical guidance.

How do these three peptide markers compare as diagnostic tools?

Three blood peptide markers — sFlt-1, PlGF, and ELABELA — measure different biological signals and answer different clinical questions. Choosing among them depends on what a clinician is trying to detect, when in pregnancy, and in which person.

sFlt-1 and PlGF: a ratio that predicts preeclampsia

sFlt-1 (soluble fms-like tyrosine kinase-1) blocks blood vessel growth. PlGF (placental growth factor) promotes it. When sFlt-1 rises and PlGF falls, blood vessel function in the placenta breaks down — the pattern seen in preeclampsia, a dangerous blood-pressure condition of pregnancy. A Revvity analytical study evaluated laboratory methods for measuring both markers and found that the sFlt-1/PlGF ratio performed with high analytical precision across multiple sample types. The trial tested the measurement tools themselves, not clinical outcomes for individual patients. Good lab performance is a prerequisite for a useful test, not proof that the test changes care.

ELABELA: an earlier, less-established signal

ELABELA is a peptide that regulates blood pressure through the same receptor system as apelin. Researchers have proposed it as an early marker for pregnancy complications. One study measured ELABELA in women in this study between 8 and 14 weeks who had been diagnosed with threatened miscarriage (abortus imminens) and found lower serum levels compared with women in uncomplicated pregnancies. The study was observational and identified an association, not a cause. The researchers did not establish whether ELABELA levels predict outcomes or whether measuring them would change clinical decisions.

Salusin-β: a metabolic signal, not a vascular one

Salusin-β is a bioactive peptide linked to inflammation and metabolic regulation. A study of women in this study found that lower serum salusin-β levels were independently associated with gestational diabetes mellitus — a condition of blood sugar dysregulation during pregnancy. This marker sits in a different category from sFlt-1/PlGF and ELABELA: it points toward metabolic risk rather than placental vascular function.

| Marker | Signal type | Pregnancy context studied | Evidence stage | |---|---|---|---| | sFlt-1 / PlGF ratio | Vascular / placental | Preeclampsia risk | Analytical validation | | ELABELA | Blood pressure regulation | Threatened miscarriage, 8–14 weeks | Observational association | | Salusin-β | Metabolic / inflammatory | Gestational diabetes | Observational association |

None of these markers is a standalone diagnosis. Each requires clinical interpretation alongside symptoms, history, and other test results.

This content is for general health education only and is not medical advice. Speak with a qualified clinician about any test, result, or treatment decision.

What are the evidence gaps that consumers should know about?

Several blood peptide markers studied in pregnancy and metabolic research have not been tested in the full range of people who use peptide products today. That's the central gap consumers need to understand. The evidence base is narrower than product marketing often suggests, and knowing where the research stops matters as much as knowing what it shows.

Who was studied — and who wasn't

Most clinical work on peptides like ELABELA, salusin-β, and placental growth factor (PlGF) focused on specific groups: pregnant women in defined gestational windows, people with diagnosed metabolic conditions, or older adults in exercise trials. This ELABELA study enrolled women between 8 and 14 weeks of pregnancy with a specific threatened-miscarriage diagnosis. Women in this study are not a stand-in for all women, and the findings don't transfer automatically to people who are not pregnant, not in that gestational window, or not experiencing that condition.

Gaps by life stage and biology

Researchers measured salusin-β levels in women with gestational diabetes in one prospective study. That study did not establish what normal salusin-β ranges look like across different ages, body compositions, or reproductive statuses outside pregnancy. PlGF and sFlt-1 assay performance was evaluated for preeclampsia screening in a laboratory validation study. The trial did not establish clinical utility for people who are not pregnant. BDNF (brain-derived neurotrophic factor) responses to resistance exercise were measured in older adults in one trial. Age, sex, and training status all affected results — the label reports variation by set number and intensity, not a uniform effect.

What the research doesn't yet answer

Long-term safety data for most peptides in non-clinical populations is thin. Interaction effects — what happens when peptides are combined, or taken alongside medications — are largely unstudied in women across different life stages. Thyroid-related findings from a study of pregnant women cannot be read as evidence about thyroid effects in people who are not pregnant. Short studies. Narrow populations. Specific conditions. Those three limits describe most of the current evidence, and any product or provider that doesn't name them is leaving out the part that matters most for your decision.

This content is for general health education only and is not medical advice. Consult a qualified healthcare provider before making any decisions about peptide medicines or other treatments.